OSR Holdings, Inc. (OSRH) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. OSR Holdings, Inc. is a global healthcare company formed via a business combination in February 2025. The company operates through four wholly-owned subsidiaries focusing on oral immunotherapies for cancer, design-augmented biologics, and neurovascular intervention medical device distribution. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $484,057 | $761,272 |
| Gross Profit | $160,281 | $168,686 |
| Gross Margin | 33.1% | 22.2% |
| Operating Loss | $(3,667,184) | $(2,917,826) |
| Net Loss | $(3,467,174) | $(11,392,814) |
| Cash and Cash Equivalents | $1,566,701 | $1,595,697 |
| Total Debt (Short & Long Term) | $7,554,246 | $6,873,451 |
| Net Cash Used in Operating Activities | $(1,001,957) | $(64,069) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 36% to $484k, primarily due to a shift in the subsidiary RMC's business model from purchase-and-resale to a consignment-based arrangement, which recognizes only commission revenue.
- Margin Expansion: Despite lower revenue, gross margin improved significantly from 22% to 33% due to the consignment model reducing cost of sales by 45%.
- Reduced Net Loss: Net loss decreased 66% to $3.47M. This improvement is largely attributable to the absence of approximately $8.5M in one-time merger-related expenses recognized in Q1 2025.
- Increased SG&A: Selling, general, and administrative expenses rose 24% to $3.83M, driven by higher personnel costs, professional fees, and public company compliance obligations.
- Acquisition Activity: The company acquired Woori-IO Co., Ltd. (a medical device and digital health platform) in January 2026, recognizing $6.4M in goodwill.
Outlook, Risks, and Unusual Items
- Subsequent Events: On April 29, 2026, the company signed a Global Exclusive License Agreement for its VXM01 asset with BCME, offering potential milestone payments up to $815 million. Additionally, a new $1.05M convertible note was issued to White Lion Capital in April 2026.
- Liquidity: The company maintains an Equity Line of Credit (ELOC) with White Lion Capital, having raised $2.11M to date. Management plans to utilize the ELOC through December 2026 but aims to minimize dilution.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to unremediated material weaknesses regarding the completeness of liabilities and sufficiency of accounting personnel.
- Legal Proceedings: Two pending lawsuits exist: one by Benjamin Securities, Inc. seeking $425k in fees, and a breach of contract complaint by Chardan Capital Markets, LLC.
- R&D Outlook: The company expects R&D expenses to range from $2.5M to $3.0M per quarter starting in the second half of 2026, potentially rising to $5.0M-$6.0M.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.57M cash balance against the projected $2.5M+ quarterly R&D burn rate and operating losses.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting to ensure future filing reliability.
- License Agreement Terms: Review the specific conditions and probability of achieving the $815M in milestone payments from the VXM01 license deal.
- Dilution Risk: Assess the impact of the ELOC and recent convertible note issuances on existing shareholder equity.
- Legal Exposure: Track the status of the pending litigation with Chardan Capital Markets and Benjamin Securities.